Diabetes UK, together with the British Heart Foundation and JDRF, have supported a landmark global study looking at Type 1 diabetes in teenagers.
It involved an incredible 4,460 teenagers across three continents, and the results have just been published in The New England Journal of Medicine.
What was the research about?
The international research team, spread across the UK, Canada and Australia, wanted to understand more about long-term complications from diabetes – such as heart and kidney problems – and how they develop in people with Type 1. They also wanted to see if there’s anything we can do during teenage years to decrease the risk of developing these complications later in life.
The trial, called AdDIT, set out to find out if taking drugs that lower blood pressure (called ACE inhibitors) and cholesterol levels (called statins), could reduce the risk of kidney, eye and heart disease in young people with Type 1 diabetes.
The results suggest that neither ACE inhibitors nor statins significantly reduce the risk of complications. But there are some signs that the drugs might have smaller benefits, which need to be investigated further. The research team also believe that the impact of the treatment might be felt further into the future, as seen in some other clinical trials.
While the treatments haven’t been shown to be effective, the research will improve our understanding of how Type 1 diabetes progresses in teenagers and open up new avenues of research into how to potentially prevent complications in the future.
Amazing international collaboration
Hope for future benefits
Sophie, a participant of the AdDIT trial since 2010, believes that taking part was beneficial for her and that every trial, no matter the final outcome, helps us understand more about the condition (she is pictured above with her diabetes nurse Sara).